Rumana Rashid

Rumana Rashid

Auto-generated profile, based on publicly available information

Rumana Rashid

Harvard Medical School

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
GGGiorgio Gaglia
Giorgio Gaglia
RRRumana Rashid
Rumana Rashid
CYClarence Yapp
Clarence Yapp
GJGaurav N. Joshi
Gaurav N. Joshi
CLCarmen G. Li
Carmen G. Li
SSSandro Santagata
Sandro Santagata

17 December 2019 in Scientific Data
Verified
Journal Article
Open access
PDF file
RRRumana Rashid
Rumana Rashid
GGGiorgio Gaglia
Giorgio Gaglia
YCYu-An Chen
Yu-An Chen
JLJia-Ren Lin
Jia-Ren Lin
ZDZiming Du
Ziming Du
SSSandro Santagata
Sandro Santagata
In this data descriptor, we document a dataset of multiplexed immunofluorescence images and derived single-cell measurements of immune lineage and other markers in formaldehyde-fixed and paraffin-embedded (FFPE) human tonsil and lung cancer tissue. We used tissue cyclic immunofluorescence (t-CyCIF) to generate fluorescence images which we artifact corrected using the BaSiC tool, stitched and registered using the ASHLAR algorithm, and segmented using ilastik software and MATLAB. We extracted single-cell features from these images using HistoCAT software. The resulting dataset can be visualized using image browsers and analyzed using high-dimensional, single-cell methods. This dataset is a valuable resource for biological discovery of the immune system in normal and diseased states as well as for the development of multiplexed image analysis and viewing tools.

15 October 2020 in Journal of Open Source Software
Verified
Journal Article
Open access
PDF file
JHJohn Hoffer
John Hoffer
RRRumana Rashid
Rumana Rashid
JMJeremy L Muhlich
Jeremy L Muhlich
YCYu-An Chen
Yu-An Chen
DRDouglas Peter William Russell
Douglas Peter William Russell
PSPeter K. Sorger
Peter K. Sorger
Advances in highly multiplexed tissue imaging are transforming our understanding of human biology by enabling detection and localization of 10-100 proteins at subcellular resolution (Bodenmiller, 2016). Efforts are now underway to create public atlases of multiplexed images of normal and diseased tissues (Rozenblatt-Rosen et al., 2020). Both research and clinical applications of tissue imaging benefit from recording data from complete specimens so that data on cell state and composition can be studied in the context of overall tissue architecture. As a practical matter, specimen size is limited by the dimensions of microscopy slides (2.5 × 7.5 cm or ~2-8 cm2 of tissue depending on shape). With current microscopy technology, specimens of this size can be imaged at sub-micron resolution across ~60 spectral channels and ~106 cells, resulting in image files of terabyte size. However, the rich detail and multiscale properties of these images pose a substantial computational challenge (Rashid et al., 2020). See Rashid et al. (2020) for an comparison of existing visualization tools targeting these multiplexed tissue images.

19 February 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
VRVeronica Rendo
Veronica Rendo
ELEudocia Q. Lee
Eudocia Q. Lee
CBConnor Bossi
Connor Bossi
NKNicholas Khuu
Nicholas Khuu
MRMichelle A. Rudek
Michelle A. Rudek
RBRameen Beroukhim
Rameen Beroukhim
Inhibitors of murine double minute homolog 2 (MDM2) represent a promising therapeutic approach for the treatment of TP53 wild-type glioblastomas (GBMs), reactivating p53 signaling to induce cancer cell death. We conducted a surgical window-of-opportunity trial (NCT03107780) of the MDM2 inhibitor navtemadlin (KRT-232) in 21 patients with TP53 wild-type recurrent GBM to determine achievable drug concentrations within tumor tissues and biological mechanisms of response and resistance. Participants received navtemadlin at 120 mg ( n = 10) or 240 mg ( n = 11) for 2 days before surgical resection and after surgery until progression or unacceptable toxicity. Both 120 and 240 mg daily dosing achieved a pharmacodynamic impact, but median progression-free survival was 3.1 months. DNA sequencing of three recurrent tumors revealed an absence of TP53 -inactivating mutations, indicating alternative mechanisms of resistance. To understand the mechanisms of response and resistance associated with navtemadlin, we conducted functional and spatial analyses of human tissue and patient-derived GBM neurosphere models. Navtemadlin induced partial tumor cell death as monotherapy, and combination with temozolomide enhanced apoptosis in GBM neurospheres while sparing normal bone marrow cells in vitro. We also observed up-regulation of oligodendrocyte differentiation genes with navtemadlin treatment and enrichment of oligodendrocyte transcription factor 2 (OLIG2)–positive cells at relapse, suggesting an unexplored mechanism of navtemadlin tolerance in GBM. Overall, these results indicated that clinically achievable doses of navtemadlin exert pharmacodynamic effects on GBM and suggest that combined treatment with temozolomide may be a route to more durable survival benefits.

30 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RRRumana Rashid
Rumana Rashid
YCYu-An Chen
Yu-An Chen
JHJohn Hoffer
John Hoffer
JMJeremy L Muhlich
Jeremy L Muhlich
JLJia-Ren Lin
Jia-Ren Lin
PSPeter K. Sorger
Peter K. Sorger
The recent development of highly multiplexed tissue imaging promises to substantially accelerate research into basic biology and human disease. Concurrently, histopathology in a clinical setting is undergoing a rapid transition to digital methods. Online tissue atlases involving highly multiplexed images of research and clinical specimens will soon join genomics as a systematic source of information on the molecular basis of disease and therapeutic response. However, even with recent advances in machine learning, experience with anatomic pathology shows that there is no immediate substitute for expert visual review, annotation, and description of tissue images. In this perspective we review the ecosystem of software available for analysis of tissue images and identify a need for interactive guides or “digital docents” that allow experts to help make complex images intelligible. We illustrate this idea using Minerva software and discuss how interactive image guides are being integrated into multi-omic browsers for effective dissemination of atlas data.

24 July 2023 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
RRRumana Rashid
Rumana Rashid
SCSusan Copelli
Susan Copelli
JSJonathan C. Silverstein
Jonathan C. Silverstein
MBMichael J. Becich
Michael J. Becich
Objective: Rare disease research requires data sharing networks to power translational studies. We describe novel use of Research Electronic Data Capture (REDCap), a web application for managing clinical data, by the National Mesothelioma Virtual Bank, a federated biospecimen, and data sharing network. Materials and Methods: National Mesothelioma Virtual Bank (NMVB) uses REDCap to integrate honest broker activities, enabling biospecimen and associated clinical data provisioning to investigators. A Web Portal Query tool was developed to source and visualize REDCap data in interactive, faceted search, enabling cohort discovery by public users. An AWS Lambda function behind an API calculates the counts visually presented, while protecting record level data. The user-friendly interface, quick responsiveness, automatic generation from REDCap, and flexibility to new data, was engineered to sustain the NMVB research community. Results: NMVB implementations enabled a network of 8 research institutions with over 2000 mesothelioma cases, including clinical annotations and biospecimens, and public users’ cohort discovery and summary statistics. NMVB usage and impact is demonstrated by high website visits (>150 unique queries per month), resource use requests (>50 letter of interests), and citations (>900) to papers published using NMVB resources. Discussion: NMVB’s REDCap implementation and query tool is a framework for implementing federated and integrated rare disease biobanks and registries. Advantages of this framework include being low-cost, modular, scalable, and efficient. Future advances to NVMB’s implementations will include incorporation of -omics data and development of downstream analysis tools to advance mesothelioma and rare disease research. Conclusion: NVMB presents a framework for integrating biobanks and patient registries to enable translational research for rare diseases.